Alignment Healthcare (ALHC) Insider Sells $550,000 in Stock

Alignment Healthcare (NASDAQ: ALHC) operates Medicare Advantage plans powered by a technology-driven care platform designed for high-need senior populations. A recent insider stock sale drew brief attention, but the company's underlying momentum — accelerating membership, swelling revenue, and a first profitable quarter — is the more consequential story.

At a Glance

• ALHC shares trading at $21.66, up 3.1% on June 21, 2026
• Market cap: $4.52 billion; 52-week range: $13.05–$22.74
• RSI: 66.94 — approaching overbought territory
• Q1 2026 revenue jumped 33.3% year-over-year to $1.24 billion
• EVP Joseph Konowiecki sold 25,000 shares on June 18 under a prearranged trading plan

The Insider Sale in Context

On June 18, 2026, Joseph S. Konowiecki, Executive Vice President of Corporate Affairs, sold 25,000 shares of ALHC common stock at $22.00 per share, generating roughly $550,000. That transaction was executed under a Rule 10b5-1 trading plan adopted in March — a prearranged schedule that insulates sales from accusations of opportunistic timing.

The sale trimmed just over 2% of his direct holdings. After the transaction, Konowiecki retained 1,153,816 shares, worth approximately $25.22 million based on the June 18 close of $21.86. That level of continued ownership signals an executive still meaningfully tied to the company's performance.

What's Actually Driving the Stock

Alignment Healthcare describes itself as a scale player in the Medicare Advantage sector, combining direct plan ownership with a proprietary technology platform to serve complex, high-cost patient populations. The business model is built around keeping members healthier and cheaper — a proposition that matters more as the broader Medicare Advantage market tightens.

First-quarter results gave investors something concrete to work with. Revenue hit $1.24 billion, up 33.3% from the same period a year earlier. Membership rose 30.9% to approximately 284,800 members. The company also swung to a net profit of $11.4 million after posting a loss in Q1 2025, and adjusted EBITDA grew nearly 88% to $37.9 million. Management responded by raising the midpoint of full-year guidance across membership, revenue, adjusted gross profit, and adjusted EBITDA.

CEO John Kao described Q1 as proof that Alignment can "grow with discipline," pointing to improvements in sales execution, clinical operations, and cost control. That kind of language from a CEO usually signals a company that has moved past the breakeven inflection point — though sustaining it over multiple quarters is a different challenge.

What the Numbers Say

At $21.66, ALHC sits near the top of its 52-week range of $13.05 to $22.74, meaning the stock has almost doubled from its annual low. The trailing twelve-month price gain stands at roughly 56.6%. That run-up compresses the margin of safety for new buyers even as the business fundamentals improve.

Trailing twelve-month revenue stands at $4.26 billion against net income of $19.81 million — thin margins that reflect both the capital-intensive nature of running health plans and the company's relatively recent crossover into profitability. A formal P/E isn't particularly meaningful at these early-profit levels, though the market is clearly pricing in continued growth.

The RSI of 66.94 puts ALHC in elevated-momentum territory without yet crossing the conventional 70 overbought threshold. Dividend: there is none, so yield-focused investors will find nothing here.

Bull case: Membership growth above 30% alongside a pivot to profitability is rare in managed care. If Alignment keeps executing on its raised guidance, the stock's proximity to its 52-week high could look justified in hindsight.

Bear case: Medicare Advantage reimbursement rates remain under political and actuarial pressure. Margins are thin enough that any medical-cost surprise could erase the company's nascent profitability. The stock is also priced close to its year-to-date ceiling, leaving little room for disappointment.

Frequently Asked Questions

Why did an Alignment Healthcare executive sell stock?

Joseph Konowiecki sold 25,000 shares under a Rule 10b5-1 plan adopted in March 2026. These prearranged plans are set up in advance and executed automatically, which limits the inference investors can draw about an insider's near-term outlook.

Does Alignment Healthcare pay a dividend?

No. ALHC does not currently pay a dividend. The company is in a growth phase, and its net income — while positive on a trailing twelve-month basis — remains modest relative to its revenue base.

How has ALHC stock performed over the past year?

As of June 2026, ALHC shares have risen approximately 56.6% over the prior twelve months. The 52-week range runs from $13.05 to $22.74, and the stock is currently trading near the upper end of that band.

What does Alignment Healthcare actually do?

The company owns and operates Medicare Advantage health plans, using a proprietary technology platform to manage care for older adults with complex medical needs. Its model integrates plan ownership with direct care management, targeting cost efficiency in a population that typically generates high medical expenses.

Where ALHC Stands Now

The insider transaction is background noise. What matters is that Alignment Healthcare posted its strongest quarterly results to date, raised full-year targets, and is growing membership at a rate few managed-care operators can match right now. The stock's proximity to its 52-week high reflects that reality — and the risk embedded in it.